Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, safety and immunogenicity of two formulations of Omalizumab (Process-Changed CMAB007 and Xolair) in healthy subjects.
Epistemonikos ID: c0d569b228dded2c291755bef09944cde233fc31
First added on: Nov 25, 2025